Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Climent

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancerJ Tabernero, M A Climent, A Lluch, et al.
Cancer Metastasis Reviews|August 1, 2015
New advances in genitourinary cancer: evidence gathered in 2014C Suárez, J Puente, E Gallardo, et al.
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
European Urology|June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial CarcinomaPetros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.
European Urology Oncology|May 3, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 TrialPetros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, et al.
BMC Cancer|February 11, 2010
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozoleZaida Garcia-Casado, Angel Guerrero-Zotano, Antonio Llombart-Cussac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyJavier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
European Urology Oncology|May 15, 2024
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS StudyXavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancerJ Tabernero, M A Climent, A Lluch, et al.
Cancer Metastasis Reviews|August 1, 2015
New advances in genitourinary cancer: evidence gathered in 2014C Suárez, J Puente, E Gallardo, et al.
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
European Urology|June 2, 2022
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial CarcinomaPetros Grivas, Evgeny Kopyltsov, Po-Jung Su, et al.
European Urology Oncology|May 3, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 TrialPetros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, et al.
BMC Cancer|February 11, 2010
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozoleZaida Garcia-Casado, Angel Guerrero-Zotano, Antonio Llombart-Cussac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II studyJavier Cortes, Serena Di Cosimo, Miguel A Climent, et al.
European Urology Oncology|May 15, 2024
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS StudyXavier García Del Muro, David Páez López-Bravo, Miler Andrés Cuéllar-Rivas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapyK Fizazi, A Ulys, L Sengeløv, et al.
The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.
Pageof 10